19.87

0.60% -0.12

After Hours: 19.87

Innoviva Inc (INVA)

Overview News Price History Option Chain Financials Discussions Forecast Dividend History

Innoviva Inc stock is traded at $19.87, with a volume of 453.49K. It is down -0.60% in the last 24 hours and down -5.29% over the past month. Innoviva Inc is a company with a portfolio of royalties healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Ellipta, Trelegy, Ellipta and others.

Previous Close:

$19.99

Open:

$19.92

24h Volume:

453.49K

Relative Volume:

0.52

Market Cap:

$1.49B

Revenue:

$384.03M

Net Income/Loss:

$38.65M

P/E Ratio:

64.10

EPS:

0.31

Net Cash Flow:

$196.35M

1W Performance:

+0.35%

1M Performance:

-5.29%

6M Performance:

+2.42%

1Y Performance:

+14.20%

1-Day Range:

$19.79

$20.20

1-Week Range:

$19.52

$20.20

52-Week Range:

$16.52

$22.76

Innoviva Inc Stock (INVA) Company Profile

Name

Innoviva Inc

Sector

Healthcare (1131)

Industry

Biotechnology (631)

Phone

(650) 238-9600

Address

1350 OLD BAYSHORE HIGHWAY, BURLINGAME

Employee

127

Twitter

Next Earnings Date

2025-10-31

Latest SEC Filings

INVA's Discussions on Twitter

Compare INVA with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
INVA Innoviva Inc	19.87	1.49B	384.03M	38.65M	196.35M	0.31
VRTX Vertex Pharmaceuticals Inc	452.13	115.03B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	776.31	81.12B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	400.17	52.54B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	839.99	51.78B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	177.12	37.12B	447.02M	-1.18B	-906.14M	-6.1812

Innoviva Inc Stock (INVA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-30-25	Initiated	Goldman	Sell
Aug-11-25	Initiated	Oppenheimer	Outperform
Jul-14-25	Initiated	H.C. Wainwright	Buy
Jul-11-25	Initiated	Cantor Fitzgerald	Overweight
Mar-07-25	Initiated	Scotiabank	Sector Outperform
Jun-18-24	Initiated	Cantor Fitzgerald	Overweight
Jul-20-22	Initiated	Goldman	Neutral
Nov-20-17	Initiated	Deutsche Bank	Hold

View All

Innoviva Inc Stock (INVA) Latest News

06:30 AM

Synergy Asset Management LLC Invests $1.85 Million in Innoviva, Inc. $INVA - MarketBeat

06:30 AM

Jan 01, 2026

Avoiding Lag: Real-Time Signals in (INVA) Movement - Stock Traders Daily

Jan 01, 2026

Dec 31, 2025

Innoviva’s Stock Under the Microscope: Is INVA Quietly Setting Up Its Next Move? - AD HOC NEWS

Dec 31, 2025

Innoviva joins elite list of stocks with 95-plus composite rating - MSN

Dec 31, 2025

Dec 29, 2025

Pacer Advisors Inc. Sells 48,889 Shares of Innoviva, Inc. $INVA - Defense World

Dec 29, 2025

Dec 28, 2025

Scotiabank Initiates Coverage of Innoviva (INVA) with Sector Outperform Recommendation - MSN

Dec 28, 2025

Is Innoviva Inc stock in correction or buying zoneJuly 2025 Reactions & Community Trade Idea Sharing Platform - moha.gov.vn

Dec 28, 2025

Dec 27, 2025

Despite Lower Earnings Than Five Years Ago, Innoviva (NASDAQ:INVA) Investors Are up 65% Since Then - 富途牛牛

Dec 27, 2025

Dec 25, 2025

Innoviva (INVA): Valuation Check After FDA Approval of First-in-Class NUZOLVENCE Antibiotic - Sahm

Dec 25, 2025

Dec 24, 2025

Innoviva (NASDAQ:INVA) Share Price Crosses Above Two Hundred Day Moving AverageHere's Why - MarketBeat

Dec 24, 2025

Innoviva Inc (NASDAQ:INVA) Nasdaq Composite ETF Therapy Royalties - Kalkine Media

Dec 24, 2025

Dec 23, 2025

Is Innoviva Inc a good long term investmentMarket Sentiment Report & Small Investment Portfolio - earlytimes.in

Dec 23, 2025

December 2026 Options Now Available For Innoviva (INVA) - Nasdaq

Dec 23, 2025

How Investors May Respond To Innoviva (INVA) Winning FDA Approval For First-In-Class Gonorrhea Drug - Sahm

Dec 23, 2025

Dec 21, 2025

H.C. Wainwright Lifts PT on Innoviva (INVA) to $46 From $45, Keeps a Buy Rating - Finviz

Dec 21, 2025

Technical Reactions to INVA Trends in Macro Strategies - Stock Traders Daily

Dec 21, 2025

Dec 20, 2025

Will Innoviva Inc. stock attract ESG investorsTrade Exit Report & Daily Profit Maximizing Trade Tips - Улправда

Dec 20, 2025

Will Innoviva Inc. (HVE) stock justify high valuation2025 Volatility Report & Weekly Watchlist for Consistent Profits - Улправда

Dec 20, 2025

Will Innoviva Inc. (HVE) stock recover faster than industryJuly 2025 Short Interest & High Return Trade Guides - Улправда

Dec 20, 2025

12 Small Cap Stocks to Buy with Huge Upside Potential - Insider Monkey

Dec 20, 2025

Can Innoviva Inc. stock deliver surprise earnings beatMarket Growth Summary & Low Drawdown Momentum Ideas - Улправда

Dec 20, 2025

Aug Fed Impact: How Innoviva Inc. (HVE) stock compares with tech leadersInsider Selling & Short-Term High Return Ideas - Улправда

Dec 20, 2025

Can Innoviva Inc. (HVE) stock deliver double digit returnsJuly 2025 Weekly Recap & Daily Stock Trend Reports - Улправда

Dec 20, 2025

Dec 19, 2025

Is Innoviva Still Attractive Around $20 After Strong Multi Year Share Price Gains? - Yahoo Finance

Dec 19, 2025

How Innoviva Inc. stock responds to policy changesQuarterly Portfolio Review & Free Safe Entry Trade Signal Reports - DonanımHaber

Dec 19, 2025

Why Innoviva Inc. stock is in analyst buy zoneWeekly Risk Summary & Stock Portfolio Risk Control - DonanımHaber

Dec 19, 2025

Is Innoviva Inc. stock positioned for digital transformationJuly 2025 Patterns & Long-Term Capital Growth Strategies - DonanımHaber

Dec 19, 2025

Can Innoviva Inc. stock deliver sustainable ROENew Guidance & Low Risk Entry Point Guides - DonanımHaber

Dec 19, 2025

Profit Recap: Can Innoviva Inc. (HVE) stock deliver double digit returnsJuly 2025 Catalysts & Weekly Stock Performance Updates - Улправда

Dec 19, 2025

Dec 18, 2025

Will Innoviva Inc. stock see PE expansion2025 Performance Recap & Capital Efficiency Focused Ideas - Улправда

Dec 18, 2025

Dec 17, 2025

Innoviva, Inc. (NASDAQ:INVA) Receives $38.60 Average Target Price from Analysts - Defense World

Dec 17, 2025

Dec 16, 2025

HC Wainwright & Co. Maintains Innoviva (INVA) Buy Recommendation - Nasdaq

Dec 16, 2025

INVA: HC Wainwright & Co. Maintains Buy Rating and Raises Price Target | INVA Stock News - GuruFocus

Dec 16, 2025

Innoviva announces Lancet publication of 'positive' Zoliflodacin Phase 3 data - MSN

Dec 16, 2025

Dec 15, 2025

U.S. FDA Approves NUZOLVENCE® (zoliflodacin), a First-in-Class, Single-dose, Oral Antibiotic for the Treatment of Uncomplicated Urogenital Gonorrhea in Adults and Adolescents - BioSpace

Dec 15, 2025

Dec 14, 2025

Innoviva Specialty Therapeutics announces FDA approval of Nuzolvence - MSN

Dec 14, 2025

Innoviva, Inc. (NASDAQ:INVA) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat

Dec 14, 2025

Innoviva (INVA): Revisiting Valuation After a Strong Multi‑Year Share Price Run - Sahm

Dec 14, 2025

Dec 13, 2025

US FDA approves Innoviva’s oral antibiotic for gonorrhea - WTAQ

Dec 13, 2025

Dec 12, 2025

US FDA approves Innoviva's oral antibiotic for gonorrhea - Reuters

Dec 12, 2025

Innoviva (NASDAQ: INVA) gets FDA approval for single-dose oral antibiotic NUZOLVENCE for gonorrhea - Stock Titan

Dec 12, 2025

Innoviva Specialty Therapeutics Announces Publication in The Lancet of Positive Zoliflodacin Phase 3 Data for the Treatment of Uncomplicated Urogenital Gonorrhea - BioSpace

Dec 12, 2025

Dec 11, 2025

Innoviva Specialty Therapeutics Announces Publication in The Lancet of Positive Zoliflodacin Phase 3 - PharmiWeb.com

Dec 11, 2025

Dec 10, 2025

Trading the Move, Not the Narrative: (INVA) Edition - Stock Traders Daily

Dec 10, 2025

Dec 08, 2025